Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China
During IL-17A inhibitor therapy, there is a need for increased awareness of annual screening and assessment of individual risk for early detection of TB infection. LTBI treatment is generally well tolerated and is effective in preventing increased IFN-γ responses in patients with psoriasis treated with IL-17A inhibitors.
Authors
- Yizhang Liu (ORCID: https://orcid.org/0009-0001-0465-2829)
- Chengzhi Lv (ORCID: https://orcid.org/0000-0002-6963-1834)
- Lü Jian (ORCID: https://orcid.org/0000-0002-7701-3649)
- Yehong Kuang (ORCID: https://orcid.org/0000-0002-1133-1791)
- Sha Yang (ORCID: https://orcid.org/0000-0003-4190-5722)
- Kun Hu (ORCID: https://orcid.org/0000-0001-9717-4012)
- Mi Zhang (ORCID: https://orcid.org/0000-0001-6795-0076)
- Yongfang Duan
Institutions
- Central South University (CN)
- National University of Defense Technology (CN)
- SKiN Health (CA)
- Hunan Cancer Hospital (CN)
- Dalian Dermatosis Hospital (CN)
- National Clinical Research (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1093/ced/llae549
- Citations
- 4
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China